Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 33c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $247.57 --0%
EPS Growth %: -20.4%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
HURC, KNOP, More
EPS Growth %: -20.4%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
HURC, KNOP, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $3.22, $0.33 better than the analyst estimate of $2.89. Revenue for the quarter came in at $412 million versus the consensus estimate of $421 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.20, versus the consensus of $10.90. Jazz Pharmaceuticals sees FY2017 revenue of $1.6-1.65 million, versus the consensus of $1.64 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
- Intel (INTC) PT Lowered to $92 at Mizuho
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
